The DURABLE Tri...
  Short Summary
    This study will compare insulin lispro low mixture [LM] and insulin glargine
both in combination with the patient's oral diabetes medicines, for their
ability to control blood sugar in patients with type 2 diabetes and compare
insulin lispro LM to insulin glargine with regard to the length of time
that the overall blood sugar can be controlled.
    Comparison of pre meals blood glucose, post meals blood glucose, average
of all blood glucose, and fasting blood glucose between those participants
who met their goal at Week 24 versus those who did not meet their goal
at Week 24 (goal HbA1c ?7.0%).
    Comparison of duration of diabetes at baseline between those participants
taking insulin glargine that maintained their HbA1c goal and those that
did not.
    Failure is defined by HbA1c> 7.0% with change>= 0.4% from most recent HbA1c
that was <=7.0%.
  Full Summary
    This study will compare insulin lispro low mixture [LM] and insulin glargine
both in combination with the patient's oral diabetes medicines, for their
ability to control blood sugar in patients with type 2 diabetes and compare
insulin lispro LM to insulin glargine with regard to the length of time
that the overall blood sugar can be controlled.
    A postprandial excursion is defined as: 2 hour postmeal plasma glucose-premeal
plasma glucose.
    Hypoglycemia = any time participant feels/person observes that the participant
is experiencing a sign/symptom they associate with hypoglycemia (such as
hunger, dizziness, shakiness, light-headedness, sweating, irritability,
headache, fast heart beat, confusion, etc) or a glucose measurement ?70
mg/dL (?3.9 mmol/L).
    Severe hypoglycemia = participant requires assistance.
    Qualified medical staff instructed the participants about the signs and
symptoms of hypoglycemia.
    Comparison of age at baseline between those participants who met their
goal at Week 24 versus those who did not meet their goal at Week 24 (goal
HbA1c ?7.0%).
    Comparison of pre meals blood glucose, post meals blood glucose, average
of all blood glucose, and fasting blood glucose between those participants
who met their goal at Week 24 versus those who did not meet their goal
at Week 24 (goal HbA1c ?7.0%).
    Comparison of oral diabetes medication at baseline between those participants
who met their goal at Week 24 versus those who did not meet their goal
at Week 24 (goal HbA1c ?7.0%).
    Comparison of duration of diabetes at baseline between those participants
taking insulin glargine that maintained their HbA1c goal and those that
did not.
    Participants who maintained goal are those who did not fail during their
duration on study.
    Failure is defined by HbA1c> 7.0% with change>= 0.4% from most recent HbA1c
that was <=7.0%.
  HbA1c (100)
    Comparison of age at baseline between those participants who met their
goal at Week 24 versus those who did not meet their goal at Week 24 (goal
HbA1c ?7.0%).
    Comparison of pre meals blood glucose, post meals blood glucose, average
of all blood glucose, and fasting blood glucose between those participants
who met their goal at Week 24 versus those who did not meet their goal
at Week 24 (goal HbA1c ?7.0%).
    Comparison of oral diabetes medication at baseline between those participants
who met their goal at Week 24 versus those who did not meet their goal
at Week 24 (goal HbA1c ?7.0%).
    Comparison of duration of diabetes at baseline between those participants
taking insulin glargine that maintained their HbA1c goal and those that
did not.
    Failure is defined by HbA1c> 7.0% with change>= 0.4% from most recent HbA1c
that was <=7.0%.
  insulin (56)
    This study will compare insulin lispro low mixture [LM] and insulin glargine
both in combination with the patient's oral diabetes medicines, for their
ability to control blood sugar in patients with type 2 diabetes and compare
insulin lispro LM to insulin glargine with regard to the length of time
that the overall blood sugar can be controlled.
    Comparison of duration of diabetes at baseline between those participants
taking insulin glargine that maintained their HbA1c goal and those that
did not.
  lispro (43)
    This study will compare insulin lispro low mixture [LM] and insulin glargine
both in combination with the patient's oral diabetes medicines, for their
ability to control blood sugar in patients with type 2 diabetes and compare
insulin lispro LM to insulin glargine with regard to the length of time
that the overall blood sugar can be controlled.
  glucose (42)
    A postprandial excursion is defined as: 2 hour postmeal plasma glucose-premeal
plasma glucose.
    Hypoglycemia = any time participant feels/person observes that the participant
is experiencing a sign/symptom they associate with hypoglycemia (such as
hunger, dizziness, shakiness, light-headedness, sweating, irritability,
headache, fast heart beat, confusion, etc) or a glucose measurement ?70
mg/dL (?3.9 mmol/L).
    Comparison of pre meals blood glucose, post meals blood glucose, average
of all blood glucose, and fasting blood glucose between those participants
who met their goal at Week 24 versus those who did not meet their goal
at Week 24 (goal HbA1c ?7.0%).
  hypoglycemia (40)
    Hypoglycemia = any time participant feels/person observes that the participant
is experiencing a sign/symptom they associate with hypoglycemia (such as
hunger, dizziness, shakiness, light-headedness, sweating, irritability,
headache, fast heart beat, confusion, etc) or a glucose measurement ?70
mg/dL (?3.9 mmol/L).
    Severe hypoglycemia = participant requires assistance.
    Qualified medical staff instructed the participants about the signs and
symptoms of hypoglycemia.
  diabetes (35)
    This study will compare insulin lispro low mixture [LM] and insulin glargine
both in combination with the patient's oral diabetes medicines, for their
ability to control blood sugar in patients with type 2 diabetes and compare
insulin lispro LM to insulin glargine with regard to the length of time
that the overall blood sugar can be controlled.
    Comparison of oral diabetes medication at baseline between those participants
who met their goal at Week 24 versus those who did not meet their goal
at Week 24 (goal HbA1c ?7.0%).
    Comparison of duration of diabetes at baseline between those participants
taking insulin glargine that maintained their HbA1c goal and those that
did not.
  baseline (31)
    Comparison of age at baseline between those participants who met their
goal at Week 24 versus those who did not meet their goal at Week 24 (goal
HbA1c ?7.0%).
    Comparison of oral diabetes medication at baseline between those participants
who met their goal at Week 24 versus those who did not meet their goal
at Week 24 (goal HbA1c ?7.0%).
    Comparison of duration of diabetes at baseline between those participants
taking insulin glargine that maintained their HbA1c goal and those that
did not.
  insulin glargine (29)
    This study will compare insulin lispro low mixture [LM] and insulin glargine
both in combination with the patient's oral diabetes medicines, for their
ability to control blood sugar in patients with type 2 diabetes and compare
insulin lispro LM to insulin glargine with regard to the length of time
that the overall blood sugar can be controlled.
    Comparison of duration of diabetes at baseline between those participants
taking insulin glargine that maintained their HbA1c goal and those that
did not.
  duration (24)
    Comparison of duration of diabetes at baseline between those participants
taking insulin glargine that maintained their HbA1c goal and those that
did not.
    Participants who maintained goal are those who did not fail during their
duration on study.
  blood glucose (21)
    Comparison of pre meals blood glucose, post meals blood glucose, average
of all blood glucose, and fasting blood glucose between those participants
who met their goal at Week 24 versus those who did not meet their goal
at Week 24 (goal HbA1c ?7.0%).
  Map created automatically by
WebSummarizer
product of Context Discovery
http://www.contextdiscovery.com
websummarizer@contextdiscovery.com